[Form 4] Impinj, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Chris Diorio, Ph.D., Chief Executive Officer and Director of Impinj, Inc. (PI), reported sales of 10,000 shares of common stock under a Rule 10b5-1 trading plan. The transactions occurred on September 2–3, 2025 and were effected under a trading plan effective May 28, 2025. The sales were reported as multiple transactions with weighted-average prices reported in ranges from $180.00 to $190.405 per share across the trades. Following the reported transactions, Dr. Diorio is shown as beneficially owning 346,109 shares directly and 199,362 shares indirectly (via DFT L.L.C.), for a combined total of 545,471 shares. The Form 4 was signed by an attorney-in-fact on behalf of Dr. Diorio on September 3, 2025.

Insights

Securities/Financial Analyst

TL;DR: Routine, prearranged insider sales totaling 10,000 shares under a 10b5-1 plan; illustrates insider liquidity, not new company information.

The filing discloses that CEO Chris Diorio sold a total of 10,000 common shares pursuant to a Rule 10b5-1 plan effective May 28, 2025, with transaction dates of September 2 and 3, 2025. Weighted-average sale prices are reported within stated ranges between $180.00 and $190.405. Post-transaction beneficial ownership totaled 545,471 shares (direct plus indirect). From a market-impact perspective, these are preplanned dispositions that comply with insider trading protocols and therefore typically convey limited new information about company performance.

Corporate Governance Expert

TL;DR: Proper use of a documented 10b5-1 plan and third-party signature indicate governance compliance around insider trading.

The Form 4 explicitly states the sales were made pursuant to a Rule 10b5-1 trading plan effective May 28, 2025, and the filing was executed by an attorney-in-fact, which aligns with standard governance practices for prearranged insider transactions. The filing discloses direct and indirect holdings separately, showing transparency in beneficial ownership. There is no indication of amendments or other atypical disclosures in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DIORIO CHRIS PH.D.

(Last) (First) (Middle)

400 FAIRVIEW AVENUE NORTH

SUITE 1200

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMPINJ INC [ PI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		4,517	D	$180.5592(2)	351,592	D
Common Stock	09/02/2025		S(1)		483	D	$181.3539(3)	351,109	D
Common Stock	09/03/2025		S(1)		80	D	$186.365	351,029	D
Common Stock	09/03/2025		S(1)		925	D	$187.9578(4)	350,104	D
Common Stock	09/03/2025		S(1)		1,438	D	$189.49(5)	348,666	D
Common Stock	09/03/2025		S(1)		2,557	D	$190.153(6)	346,109	D
Common Stock								199,362	I	by DFT L.L.C.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported by Dr. Diorio were effected pursuant to a Rule 10b5-1 trading plan effective on May 28, 2025.

2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.82, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

3. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $181.185 to $181.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

4. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $187.8650 to $188.4050, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

5. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $188.9201 to $189.8300, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

6. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $190.0000 to $190.4050, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

	/s/ Yukio Morikubo, Attorney in fact for Chris Diorio	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Impinj (PI) CEO Chris Diorio sell and when?

The Form 4 shows Chris Diorio sold a total of 10,000 common shares on September 2–3, 2025.

Were the sales by Chris Diorio preplanned under a trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan effective May 28, 2025.

How many shares does Chris Diorio beneficially own after these transactions?

Following the reported transactions, Dr. Diorio beneficially owns 346,109 shares directly and 199,362 shares indirectly, totaling 545,471 shares.

What price ranges were the shares sold at?

The filing reports aggregate weighted-average prices and notes sales executed at prices ranging from $180.00 to $190.405 across the transactions.

Who signed the Form 4 on behalf of Chris Diorio?

The Form 4 was signed by Yukio Morikubo, Attorney-in-fact for Chris Diorio on September 3, 2025.